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Abstract
Coxiella burnetii, the causative agent of Q fever, is a zoonosis that causes both acute 
and	chronic	disease	in	humans.	Few	cases	have	been	reported	in	solid	organ	transplant	
recipients, and this case highlights the need to include Q fever in the differential diag-
nosis for fever of unknown origin in solid organ transplant hosts.
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1  | INTRODUCTION
Coxiella burnetii is an obligate, intracellular bacterium, and the cause 
of the zoonosis Q fever. Q fever (from “query”) was named in 1935 
following an outbreak of febrile illness in an abattoir in Queensland, 
Australia.	Acute	 disease	 in	 humans	 varies	 from	 asymptomatic	 sero-
conversion, to a non- specific flu- like illness. Rarely, complications and 
chronic disease can occur, most often endocarditis.1
Literature	 review	of	 the	medical	 databases	PubMed	and	Medline	
using	 the	 search	 terms	 “Q	 fever,”	 “Coxiella,”	 “transplant,”	 and	 “immu-
nocompromised” revealed a paucity of information on Q fever in solid 
organ transplant hosts, and no reported case in an adult liver transplant. 
We therefore, to the best of our knowledge, report the first documented 
case of Q fever in an adult liver transplant patient. We also review the 
previously published cases of Q fever in solid organ transplant.
2  | CASE REPORT
A	51-	year-	old	Egyptian	man	with	hepatitis	C-	related	cirrhosis	under-
went orthotopic liver transplant in 2007. His maintenance immuno-
suppressive regimen included mycophenolate mofetil and tacrolimus. 
He also had a history of latent tuberculosis and had completed 
9 months of isoniazid after transplantation. In addition, he had devel-
oped insulin- dependent diabetes mellitus.
Seven	years	after	 transplantation,	he	presented	with	2	months’	
duration of fevers. The patient had routine dental work completed 
with	antibiotic	prophylaxis,	and	noted	daily	fevers	around	that	time,	
for which he took acetaminophen twice daily. With the fever, he had 
associated chills, rigors, palpitations, fatigue, and myalgias. He de-
nied any mouth or jaw pain. He also denied weight loss, night sweats, 
nausea, vomiting, diarrhea, rash, arthralgias, or cough. He worked as 
a	taxi	driver,	but	had	not	worked	in	over	a	month	because	of	fevers	
and fatigue. He lived with his wife and four children at home, none 
of	whom	 had	 been	 sick	 recently.	 Approximately	 1	month	 prior	 to	
feeling ill, he travelled to Egypt to visit family. He stayed in an urban 
area, although did drive in rural areas with the windows down. He 
denied drinking unpasteurized milk or eating unpasteurized cheese. 
He did not have pets at home, and denied any hobbies and injection 
drug use.
His physical evaluation was unremarkable. He was afebrile and 
normotensive. He was without facial pain or poor dentition, hepato-
megaly, or cardiac murmur or stigmata of endocarditis. His initial labo-
ratory evaluation demonstrated normal kidney function, liver function, 
and blood counts. Negative infectious work- up included Epstein- Barr 
virus	polymerase	chain	reaction	(PCR),	cytomegalovirus	PCR,	Brucella 
serologies,	blood	culture,	and	acid-	fast	bacilli	blood	culture.	Computed	
 tomography scan of the chest, abdomen, and pelvis was unremark-
able. Transthoracic echocardiography was performed, and showed 
normal valvular function.
His Coxiella burnetii serologies returned with phase I and II 
immunoglobulin	 (Ig)G	 positive	 results	 (both	 1:128),	 IgM	 negative	
(Table	1).	 Follow-	up	 testing	 1	week	 later	 showed	 an	 increase	 in	
phase II IgG to 1:512, while phase I IgG remained 1:128. He was 
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diagnosed	with	acute	Q	fever,	and	started	on	doxycycline	100	mg	
twice	daily.	After	approximately	2	weeks	of	therapy,	his	fevers	com-
pletely resolved, and his energy level had improved. He completed 
4	weeks	 of	 doxycycline	 therapy.	 Serologies	 checked	 at	 5	weeks	
and 7 months remained elevated (both 1:128), but the patient was 
 asymptomatic, so the plan was continued monitoring.
One year after the initial diagnosis, the patient presented to clinic 
with	complaints	of	severe	fatigue	and	chills	for	2	months.	Serologies	
were repeated, and showed an increase in phase II IgG to 1:256. He 
had no other symptoms or lab abnormalities, and repeat echocardio-
gram was stable and without vegetation. The differential was chronic 
fatigue post Q fever vs chronic Q fever with an inadequate serologic 
response	in	an	immunosuppressed	patient,	so	he	was	started	on	doxy-
cycline	and	hydroxychloroquine	therapy	for	potential	chronic	Q	fever.	
Within 4 weeks, his symptoms had resolved, and at 3 months after 
this therapy, his serologies had decreased (phase I 1:64, phase II 1:32).
3  | DISCUSSION
Q fever, a zoonosis caused by the intracellular bacterium C. bur-
netii,	 causes	disease	worldwide	with	 few	exceptions,	 such	as	New	
Zealand. Ticks are the main reservoir, but mammals, birds, and 
 arthropods may be reservoirs, most notably farm animals.2 It is 
primarily	 transmitted	by	 the	aerosol	 route,	 in	particular	exposures	
from parturient cattle. Ingestion of unpasteurized milk or cheese, 
mother- to- child, and very rarely human- to- human transmission are 
also possible. However, transmission is also present without known 
animal	contact	or	ingestion,	with	likely	wind	exposure	bringing	the	
bacterium long distances.3
In immunocompetent hosts with acute Q fever, up to 50% are 
asymptomatic. If symptoms present, they are non- specific, includ-
ing fever, malaise, myalgias, headache, chills, non- productive cough, 
abdominal	pain,	nausea,	vomiting,	and	diarrhea.	Complications	 in-
clude myocarditis, granulomatous hepatitis, pneumonia, neurologic 
complications,	 and	 miscarriage	 or	 pre-	term	 labor.	 Less	 than	 5%	
develop chronic Q fever, with pregnancy, valvular heart disease or 
prosthesis, or older age as risk factors for development of chronic 
infection.1,4
Only three cases of Q fever have been described in solid organ 
transplant patients, although it is often listed as consideration in the 
differential for fever of unknown origin in an immunocompromised 
host. These cases were two renal transplants in adults5,6 and one fetal 
liver and thyroid transplant for a child with severe combined immuno-
deficiency who also developed acute lymphocytic leukemia7 (Table 2). 
All	three	patients	survived.
More	cases	are	described	in	non-	transplant	immunocompromised	
hosts. Those include patients with rheumatoid arthritis, ankylosing 
spondylitis,	 and	 psoriasis	 on	 anti-	tumor	 necrosis	 factor	 (TNF)-	alpha	
therapy,	 and	 patients	 with	 human	 immunodeficiency	 virus,	 Crohn’s	
disease,	Hodgkin’s	disease,	acute	myeloid	leukemia,	acute	lymphocytic	
leukemia, and bone marrow transplant.8-13 Overall outcomes are posi-
tive, with low morality rates.
Treatment	for	acute	Q	fever	 is	typically	doxycycline	for	2	weeks.	
The ideal duration of therapy for acute Q fever in solid organ trans-
plant patients is unknown, and in case reports of immunocompromised 
hosts, typically longer durations have been used. In addition, whether 
or not a transplant patient on immunosuppression would mount an 
adequate serological response, particularly in the setting of chronic Q 
fever, is also unknown, although an adequate serologic response for 
TABLE  1 Q fever serological results
Initial visit (t) t + 1 week t + 5 weeks t + 7 months t + 12 months t + 15 months
Phase	I IgG 1:128 1:128 1:128 1:128 1:128 1:64
Phase	II IgG 1:128 1: 512 1:128 1:128 1:256 1:32
Phase	I IgM <1:16 <1:16 <1:16 <1:16 <1:16 <1:16
Phase	II IgM <1:16 <1:16 <1:16 <1:16 <1:16 <1:16
t,	titer;	IgG,	immunoglobulin	G;	IgM,	immunoglobulin	M.
TABLE  2 Reported cases of Q fever in solid organ transplants
Author 
(reference)
Age years, 
gender, organ Country
Time since 
transplant
Immunosuppression 
regimen
Clinical 
manifestations
Diagnostic 
confirmation
Treatment, 
duration Outcome
Larsen	
et al.5
56, male, 
kidney
United	
States
1.5 years Tacrolimus, 
sirolimus, 
prednisone
Acute,	complicated	
by pneumonia, 
glomerulonephritis
Q fever 
serologies
Doxycycline,	
4.5 weeks
Survived
Godinho 
et al.6
60, male, 
kidney
Portugal NA Sirolimus,	mycophe-
nolate mofetil, 
prednisolone
Chronic,	prolonged	
fever, anemia
Q fever 
serologies
Doxycycline	
and 
hydroxychlor-
oquine,	NA
Survived
Loudon	
et al.7
5, female, 
fetal liver + 
thyroid
United	
Kingdom
4 years NA Acute,	then	chronic,	
fevers
Q fever 
serologies
Tetracycline 
IV, 4 months
Survived
NA,	not	available.	IV,	intravenously.
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diagnosis of chronic Q fever was evident in a case of a patient on an 
anti-	TNF-	alpha	agent.8
We	treated	our	patient	with	4	weeks	of	doxycycline,	 and	at	 the	
end of therapy his symptoms had resolved and he had a decrease in 
serological titers, although not complete resolution. In acute Q fever, 
phase II titers predominate and are greater than phase I.14 Titers typ-
ically	peak	at	14	days	and	then	persist	 for	10-	12	weeks.	Six	months	
after therapy, our patient remained clinically well.
However, at 1 year post therapy, he developed fatigue and chills, 
and he had a small increase in phase II titers. Typically, phase I IgG 
>800 is diagnostic of chronic Q fever, one reason it is important to 
continue to monitor serologies for a decrease in titers over time. 
While a diagnosis of chronic fatigue after Q fever was considered,15 
therapy was initiated for possible chronic Q fever, given our concern 
for an inadequate serologic response in the setting of immunosup-
pression. On therapy, his symptoms resolved and his titers have now 
decreased.
To the best of our knowledge, this is the first described case of 
acute Q fever in an adult patient after liver transplantation. This high-
lights the need to consider Q fever in the differential diagnosis for 
fever of unknown origin in a liver transplant patient, even without di-
rect	animal	exposure.
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